|
1
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kiyosawa K, Umemura T, Ichijo T, et al:
Hepatocellular carcinoma: recent trends in Japan. Gastroenterology.
127 (Suppl 1):S17–S26. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Noda I, Kitamoto M, Nakahara H, et al:
Regular surveillance by imaging for early detection and better
prognosis of hepatocellular carcinoma in patients infected with
hepatitis C virus. J Gastroenterol. 45:105–112. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shiratori Y, Shiina S, Teratani T, et al:
Interferon therapy after tumor ablation improves prognosis in
patients with hepatocellular carcinoma associated with hepatitis C
virus. Ann Intern Med. 138:299–306. 2003. View Article : Google Scholar
|
|
5
|
Mazzaferro V, Romito R, Schiavo M, et al:
Prevention of hepatocellular carcinoma recurrence with
alpha-interferon after liver resection in HCV cirrhosis.
Hepatology. 44:1543–1554. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iwasaki Y, Ikeda H, Araki Y, et al:
Limitation of combination therapy of interferon and ribavirin for
older patients with chronic hepatitis C. Hepatology. 43:54–63.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fernandez-Rodriguez CM, Alonso S, Martinez
SM, et al: Peginterferon plus ribavirin and sustained virological
response in HCV-related cirrhosis: outcomes and factors predicting
response. Am J Gastroenterol. 105:2164–2173. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mason AL, Lau JY, Hoang N, et al:
Association of diabetes mellitus and chronic hepatitis C virus
infection. Hepatology. 29:328–333. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kawaguchi T, Yoshida T, Harada M, et al:
Hepatitis C virus down-regulates insulin receptor substrates 1 and
2 through up-regulation of suppressor of cytokine signaling 3. Am J
Pathol. 165:1499–1508. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shintani Y, Fujie H, Miyoshi H, et al:
Hepatitis C virus infection and diabetes: direct involvement of the
virus in the development of insulin resistance. Gastroenterology.
126:840–848. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen CL, Yang HI, Yang WS, et al:
Metabolic factors and risk of hepatocellular carcinoma by chronic
hepatitis B/C infection: a follow-up study in Taiwan.
Gastroenterology. 135:111–121. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Imai K, Takai K, Nishigaki Y, et al:
Insulin resistance raises the risk for recurrence of stage I
hepatocellular carcinoma after curative radiofrequency ablation in
hepatitis C virus-positive patients: a prospective, case series
study. Hepatol Res. 40:376–382. 2010. View Article : Google Scholar
|
|
13
|
Miyazaki Y, Mahankali A, Matsuda M, et al:
Improved glycemic control and enhanced insulin sensitivity in type
2 diabetic subjects treated with pioglitazone. Diabetes Care.
24:710–719. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Khattab M, Emad M, Abdelaleem A, et al:
Pioglitazone improves virological response to peginterferon
alpha-2b/ribavirin combination therapy in hepatitis C genotype 4
patients with insulin resistance. Liver Int. 30:447–454. 2010.
View Article : Google Scholar
|
|
15
|
Harrison SA, Hamzeh FM, Han J, Pandya PK,
Sheikh MY and Vierling JM: Chronic hepatitis C genotype 1 patients
with insulin resistance treated with pioglitazone and peginterferon
alpha-2a plus ribavirin. Hepatology. 56:464–473. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rumi MA, Sato H, Ishihara S, et al:
Peroxisome proliferator-activated receptor gamma ligand-induced
growth inhibition of human hepatocellular carcinoma. Br J Cancer.
84:1640–1647. 2001. View Article : Google Scholar
|
|
17
|
Borbath I, Leclercq I, Moulin P, Sempoux C
and Horsmans Y: The PPARgamma agonist pioglitazone inhibits early
neoplastic occurrence in the rat liver. Eur J Cancer. 43:1755–1763.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hassan MM, Curley SA, Li D, et al:
Association of diabetes duration and diabetes treatment with the
risk of hepatocellular carcinoma. Cancer. 116:1938–1946. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lai SW, Chen PC, Liao KF, Muo CH, Lin CC
and Sung FC: Risk of hepatocellular carcinoma in diabetic patients
and risk reduction associated with anti-diabetic therapy: a
population-based cohort study. Am J Gastroenterol. 107:46–52. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
American Diabetes Association, . Diagnosis
and classification of diabetes mellitus. Diabetes Care. 33 (Suppl
1):S62–S69. 2010. View Article : Google Scholar
|
|
21
|
Akaike H: A new look at the statistical
model identification. IEEE Trans Automat Control. 19:716–723. 1974.
View Article : Google Scholar
|
|
22
|
Kawaguchi A, Yonemoto K, Tanizaki Y,
Kiyohara Y, Yanagawa T and Truong YK: Application of functional
ANOVA models for hazard regression to the Hisayama data. Stat Med.
27:3515–3527. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tonan T, Fujimoto K, Qayyum A, et al:
Quantification of hepatic iron concentration in chronic viral
hepatitis: usefulness of T2-weighted single-shot spin-echo
echo-planar MR imaging. PLoS One. 7:e338682012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ishikawa T: Strategy for improving
survival and reducing recurrence of HCV-related hepatocellular
carcinoma. World J Gastroenterol. 19:6127–6130. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rizvi AA: Metabolic markers of insulin
resistance in overweight persons. Ann Intern Med. 141:243–244.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Saito K, Inoue S, Saito T, et al:
Augmentation effect of postprandial hyperinsulinaemia on growth of
human hepatocellular carcinoma. Gut. 51:100–104. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Singh S, Singh PP, Singh AG, Murad MH and
Sanchez W: Anti-diabetic medications and the risk of hepatocellular
cancer: a systematic review and meta-analysis. Am J Gastroenterol.
108:881–892. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Park EJ, Lee JH, Yu GY, et al: Dietary and
genetic obesity promote liver inflammation and tumorigenesis by
enhancing IL-6 and TNF expression. Cell. 140:197–208. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nakagawa H, Maeda S, Yoshida H, et al:
Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic
hepatitis C patients: an analysis based on gender differences. Int
J Cancer. 125:2264–2269. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ohki T, Tateishi R, Shiina S, et al:
Visceral fat accumulation is an independent risk factor for
hepatocellular carcinoma recurrence after curative treatment in
patients with suspected NASH. Gut. 58:839–844. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Saxena NK, Fu PP, Nagalingam A, et al:
Adiponectin modulates C-jun N-terminal kinase and mammalian target
of rapamycin and inhibits hepatocellular carcinoma.
Gastroenterology. 139:1762–1773. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fukushima N, Kuromatsu R, Arinaga-Hino T,
et al: Adipocytokine involvement in hepatocellular carcinoma after
sustained response to interferon for chronic hepatitis C. Hepatol
Res. 40:911–922. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sumie S, Kawaguchi T, Kuromatsu R, et al:
Total and high molecular weight adiponectin and hepatocellular
carcinoma with HCV infection. PLoS One. 6:e268402011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Endo Y, Suzuki M, Yamada H, et al:
Thiazolidinediones enhance sodium-coupled bicarbonate absorption
from renal proximal tubules via PPARgamma-dependent nongenomic
signaling. Cell Metab. 13:550–561. 2011. View Article : Google Scholar
|
|
35
|
Kohlroser J, Mathai J, Reichheld J, Banner
BF and Bonkovsky HL: Hepatotoxicity due to troglitazone: report of
two cases and review of adverse events reported to the United
States Food and Drug Administration. Am J Gastroenterol.
95:272–276. 2000. View Article : Google Scholar
|
|
36
|
Guo L, Zhang L, Sun Y, et al: Differences
in hepatotoxicity and gene expression profiles by anti-diabetic
PPAR gamma agonists on rat primary hepatocytes and human HepG2
cells. Mol Divers. 10:349–360. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kaplowitz N: Avoiding idiosyncratic DILI:
two is better than one. Hepatology. 58:15–17. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chase MP and Yarze JC:
Pioglitazone-associated fulminant hepatic failure. Am J
Gastroenterol. 97:502–503. 2002. View Article : Google Scholar : PubMed/NCBI
|
